JATT Acquisition announced that its shareholders voted in favor of the business combination with Zura Bio Limited, a clinical-stage biotechnology company.
About 95.5% of JATT’s issued and outstanding shares were present voted. The SPAC said 99.9% of the votes cast at the meeting were in favor of the business combination.
Neither the press release announcing the vote nor a subsequent 8-K filing revealed information about redemptions, if any. However, even if redemptions completely wiped out the SPAC’s trust, JATT should still have sufficient funds between a forward purchase agreement and PIPE to fulfill the $65 million minimum cash condition to close.
At closing, which is expected March 20 after all closing conditions are satisfied or waived, Zura shares and warrants are expected to begin trading March 21 on the Nasdaq under new ticker symbols ZURA and ZURAW. Read more.
